||**Trustees' Annual Report**|**Trustees' Annual Report**|**for theperiod**|
|---|---|---|---|
||**From**|Period start date<br>**To**<br>**01**<br>**01**<br>**2025**|Period end date|
||||**31**<br>**12**<br>**2025**|
|||||
|Section A||Reference and administration details||



**Charity name BRITISH and IRISH HYPERTENSION SOCIETY** 

**Other names charity is known by BIHS Registered charity number (if any) 287635** 

**Charity's principal address** The Wolfson Institute, Charterhouse Square, London 

EC1M 6BQ 

## **Names of the charity trustees who manage the charity** 


**----- Start of picture text -----**<br>
Name of person<br>(or body) entitled<br>Trustee name  Office (if any)  Dates acted if not for whole year<br>to appoint trustee<br>(if any)<br>1 Ian Wilkinson  President  19.09.2023 – 31.12.2025<br>2 Phil Chowienczyk  Vice President  19.09.2023 – 31.12.2025<br>3 James Sheppard  Secretary  14.09.2021 – 31.12.2025<br>4 Luca Faconti  Treasurer  17.09.2022 – 31.12.2025<br>5 Helen Warren  Ordinary Member  10.09.2024 – 31.12.2025<br>Ryan McNally  Young Investigator  10.09.2024 – 31.12.2025<br>6<br>Representative<br>7 Manish Saxena  Ordinary Member   10.09.2024 – 31.12.2025<br>8 Pankaj Gupta  Ordinary Member  13.09.2022 – 15.11.2025<br>9 Sam Olden  Ordinary Member  13.09.2022 – 31.12.2025<br>**----- End of picture text -----**<br>


**Names of the trustees for the charity, if any, (for example, any custodian trustees)** 

**Name Dates acted if not for whole year** 

## **Names and addresses of advisers (Optional information)** 


**----- Start of picture text -----**<br>
Type of adviser Name Address<br>Accountant  HJS (Reading)  3 Richfield Place, Richfield Avenue, Reading, Berks, RG1 8EY.<br>Limited – part of<br>‘Fortus’<br>**----- End of picture text -----**<br>


## **Name of chief executive or names of senior staff members (Optional information)** 

**April 2009** 

**TAR** 

1 



## **Section B              Structure, governance and management** 

## **Description of the charity’s trusts** 

Constitution (adopted 21[st] October 1983, amended 24[th] September 1984, 15[th] Type of governing document September 2009, 9[th] September 2013, 22[nd] September 2014, 21[st] September (e.g. trust deed, constitution) 2015, 22[nd] September 2016, 25[th] September 2018, 13[th] September 2022) Association How the charity is constituted (e.g. trust, association, company) Trustees are elected to membership of the Executive Committee by BIHS Trustee selection methods Members at the Annual Business Meeting which primarily takes place in (e.g. appointed by, elected by) September, following a call for nominations earlier in the year 

## **Additional governance issues (Optional information)** 

Ordinary and Associate Membership and Fellowship of the BIHS is open to all You **may choose** to include registered healthcare professionals and clinical practitioners active in the field of additional information, where hypertension and cardiovascular disease prevention in the United Kingdom and relevant, about: the Republic of Ireland.  Affiliate membership may be granted to healthcare  policies and procedures professionals residing outside the United Kingdom and Republic of Ireland at the adopted for the induction discretion of the Executive Committee.   It includes consultants, clinicians, and training of trustees; nurses, physiologists, pharmacists, allied healthcare professionals, and other  the charity’s organisational  the charity’s organisational scientists.  Applications for membership are considered throughout the year. structure and any wider Only members and fellows resident in the United Kingdom and Republic of network with which the Ireland are eligible for election to the Executive Committee. 

- the charity’s organisational  the charity’s organisational structure and any wider network with which the charity works; 

- relationship with any related parties; 

   - The management of the BIHS has been undertaken by an elected Executive Committee of 9 persons (Trustees), led by the President and Vice President.  Four Standing Committees and two special interest Groups, and one communication panel have also been established to help the Executive Committee manage the day-to-day activities of the Society (at least one Trustee sits on each of the Standing Committees, which are required to submit regular reports to the Executive Committee on its activities). 

- trustees’ consideration of major risks and the system and procedures to manage them. 

The Society is in the process of changing to be a Charitable Incorporated Organisation from being an Unincorporated charity. The intention once established is that a detailed risk assessment programme will be undertaken. In the meantime the Trustees are comfortable that ongoing risks are being managed and mitigated. 

## **Section C                    Objectives and activities** 

|**Section C**|**Objectives and activities**|
|---|---|
|**Summary of the**<br>**objects of the charity**<br>**set out in its**<br>**governing document**<br>**Summary of the**<br>**main activities**<br>**undertaken for**<br>**the public benefit**<br>**in relation to**<br>**these objects**<br>**(include within**<br>**this section the**<br>**statutory**|The object of the Charity is to promote the advancement of knowledge and dissemination<br>of information concerning the pathophysiology, epidemiology, detection, investigation<br>and treatment of arterial hypertension and related cardiovascular diseases|
||The main activities undertaken for public benefit include the following:<br><br>Educational Meetings:  Each year, the Society aims to run a main Scientific Meeting.<br>Educational programmes are under review and online options are being explored.<br>Various other meetings are held during the year; in collaboration with other cognate<br>societies and/or as ad hoc meetings on specific topics. The society are also looking<br>to create more electronical educational materials in the form of videos, webinars,<br>online modules, etc.|



**April 2009** 

**TAR** 

2 



- **declaration that**  Guidelines and Scientific Statements:  The Society is a stakeholder in various **trustees have had** National Institute for Clinical Excellence Guidelines relating to cardiovascular **regard to the** disease and issues statements in response to relevant media reports **guidance issued**  Website:  The BIHS website (www.bihs.org.uk) provides a valuable educational **by the Charity** resource for healthcare professionals working in the field of high blood pressure. 

- **Commission on** Given fast moving technology, significant investment was deemed necessary to 

- **public benefit)** launch a new website since year end whilst at the same time engaging modern processes; for example being able to book efficiently online for events. 

- Blood Pressure Measurement:  The BIHS undertakes reviews of blood pressure monitors to ensure their suitability for the public and has produced a DVD on the correct procedures for blood pressure measurement.  As part of the Society’s improving blood pressure measurement, the Society undertakes active validation of new blood pressure devices for the measurement of blood pressure, thus ensuring that devices sold in the UK provide accurate measurements so that members of the public can be treated appropriately by their physicians. The BP monitors list on the Society’s website is an invaluable source for healthcare professionals when searching for accurate devices for use. 

   - Collaborative Research:  The Society has a policy to encourage and endorse suitable research projects and is actively seeking the views of the public to establish where there is a need for research into topic areas that they feel are needed. During the year, a Delphi study was underway to look at prioritising the activities of the committee. 

   - Early Career Researchers’ Special Interest Group: The Society has set up a group to encourage younger members to share their research and to become more involved in the Society’s activities.  The aim is to nurture and mentor young researchers for future population benefit. 

The Trustees have read the guidance issued by the Charity Commission relating to public benefit and can confirm that the above activities of the BIHS benefit the public in general by improving knowledge in the field of hypertension and cardiovascular disease, fostering the translation of novel clinical research and basic science into best clinical practice and therefore improving healthcare.  The charity has a track record of producing internationally renowned guidelines for the management of hypertension which are widely adopted in primary care in the UK and elsewhere.  There are no restrictions to this overall benefit in healthcare, as outlined in the Charity Commission guidance (e.g. in terms of access, geography, membership, ability to pay etc.). 

## **Additional details of objectives and activities (Optional information)** 

You **may choose** to include further statements, where relevant, about: 

Members of the Society who facilitate/contribute to the Education programmes, do so on a voluntary basis. 

- policy on grantmaking; 

- policy programme related investment; 

The Society presently invests some funds in an Ethical Investment fund. 

- contribution made by volunteers. 

## Section D                      Achievements and performance 

## **Overview of the year** 

Summary of 2025 was a year of substantial organisational change for the British and Irish Hypertension the main Society (’the Society’). Building on the strategic review and member consultation undertaken in achievemen 2024, the Society moved its core operations in-house, launched a new website and membership ts of the management system, and developed the governance and income arrangements needed to charity support its ambitions. during the year 

The purpose of this work was to give the Society the capacity to do more with its scientific and clinical expertise: support professionals, improve public understanding of blood pressure, 

**April 2009** 

**TAR** 

3 



Section D                      Achievements and performance 

influence prevention policy and help shape the responsible use of new technologies. Alongside the operational transformation, the Society continued its scientific and educational activity and strengthened relationships across healthcare, research, patient organisations and industry. The year also established a direction for longer-term structural change. Members approved the move towards charitable incorporation, discussions continued with Blood Pressure UK about closer collaboration, and BIHS convened a national summit on wearable blood pressure technology. These developments created a foundation for the Society’s next stage of work. 

## **From strategic review to implementation** 

The 2024 review drew on a membership survey, stakeholder interviews, an assessment of the external environment and an analysis of the resources required for growth. Members supported a more visible and collaborative Society, with stronger public engagement and policy influence. In 2025, the Transformation and Restructure Teams translated that direction into operational changes and recommendations to the Executive Committee, supported by an experienced strategic consultant. 

## **Operational and digital transformation** 

The Society established a dedicated virtual office and brought core administration and financial management under more direct internal oversight. External support was engaged to support administration, events, fundraising, financial management and the transition. The handover of the Society’s operations from the previous General Secretariat provider was completed in May. This required substantial work to retrieve, review and organise records, cleanse membership information and prepare content for the new systems. Microsoft Office, SharePoint and the Society’s email arrangements formed part of the virtual office setup. Standard operating procedures were developed as processes were established, to improve consistency and make future handovers less dependent on individual knowledge. The new website and customer relationship management system launched in May, following procurement, design approval, content migration and training. The platform brought together membership administration, communications and Annual Scientific Meeting registration, abstract submission and sponsorship information. This was an important step towards a more coherent service for members and other users. 

The transition identified areas for improvements that could be made in internal controls across the organisation having regards to the size and with practical solutions therewith. 

## **Membership and professional engagement** 

The Executive Committee approved a revised membership structure and Direct Debit payment model in March. These were incorporated into the new website and membership system, alongside a review and clean-up of legacy data. The aim was to improve the joining and renewal experience, make membership records more reliable and address weaknesses in subscription collection. 

Membership reopened with the new platform in May. Subsequent reporting recorded a number of new members, an encouraging response to the relaunch. The new system will also allow active analysis e.g of retention rates etc. 

Three membership webinars were held in May to explain the Society’s direction, discuss restructuring and gather feedback on closer working with Blood Pressure UK. These supplemented written communications and gave members an opportunity to question and contribute to the changes. 

An affiliation with the UK Kidney Association was announced in connection with World Hypertension Day. Discussions with the Primary Care Cardiovascular Society and other professional bodies explored reciprocal relationships and shared activity, reflecting the importance of hypertension across specialties and primary care. 

## **Governance and organisational development** 

Governance was reviewed alongside the operating model, with attention to the responsibilities of the Executive Committee, committees and operational support team. Restructure and governance proposals were presented at the Board meeting in April, following individual briefings 

**April 2009** 

**TAR** 

4 



Section D                      Achievements and performance 

with Executive Committee members. Work continued on role descriptions, reporting arrangements and alignment with the Society’s strategy. 

At the Annual Business Meeting in September 2025, members approved the move towards a Charitable Incorporated Organisation. This provided a mandate to progress the legal and constitutional work. The legal and constitutional implementation remained in progress at year end. 

A renowned charity experienced legal firm was commissioned to advise on the potential structure of closer working with Blood Pressure UK. Discussions considered how the Society’s professional and scientific expertise could complement Blood Pressure UK’s public and patient focus. Member engagement and initial preparation for due diligence took place, while the final structure, approvals and implementation remained matters for further work. 

## **Partnerships and income development** 

The Prevention Partners programme, approved in 2024, provided a framework for developing annual beneficial relationships with Pharma and other medical related entities promoting the Society’s key charitable aims during 2025 with an agreed contribution. The programme was designed as well as promoting the key Society aims to provide a more predictable income base for the Society’s activities and operating capacity. 

Sponsorship and exhibition activity for the Annual Scientific Meeting was developed alongside the new website. A number of exhibitors confirmed their attendance at an early stage as an updated exhibition brochure had been circulated. These commitments demonstrated interest in engaging with the Society’s scientific community and greatly enhanced the meeting’s financial contribution to the Society. 

## **Scientific exchange and the Annual Scientific Meeting** 

The 2025 Annual Scientific Meeting took place in Cambridge, providing a focus for the Society’s scientific community and professional exchange. The operational team supported the meeting through the new registration and abstract systems, sponsor engagement and exhibition planning. 

The meeting was well received, and the income generation was welcome due to an increased take up of external exhibitors and delegate attendees. 

## **Policy and public engagement** 

The Society worked to strengthen its presence in national cardiovascular prevention discussions. Building on its response to the Government’s 10-Year Health Plan consultation in December 2024, the Society communicated its expertise and priorities to policymakers during 2025. Correspondence included engagement with the Secretary of State for Health, the Chair of the Health and Social Care Committee and the Parliamentary Under-Secretary for Health. The reports identified a need for more systematic policy engagement after BIHS was absent from some major cardiovascular discussions. Work therefore began on a stakeholder engagement strategy and proposals for a clearer policy support structure. Contacts with national health inequalities teams and registration as a stakeholder for the NICE Quality Standard on Obesity offered further routes to contribute expertise. 

Public awareness activity included an event at the Arsenal Hub in April 2025, at which 30 Women voluntarily received blood pressure checks. The event, developed with Heartbeat of Football and Blood Pressure UK, provided an opportunity to take blood pressure awareness into a sporting setting and explore further collaboration. 

Three Beatwise podcasts featuring BIHS contributors were released in May to support May Measure Month and World Hypertension Day. These were promoted alongside member communications encouraging participation in awareness activity. Together, the event and digital content broadened the ways in which the Society shared its expertise beyond its established professional audience. 

**April 2009** 

**TAR** 

5 



## **Blood pressure technology and innovation** 

The Society reviewed its blood pressure monitor service in response to changing technology and concerns about the clarity and timeliness of existing processes. A working group considered how the Society’s expertise could extend to a wider range of non-pharmaceutical blood pressure technologies. 

During the website transition, work began to improve device submission, review and invoicing processes and the presentation of information for professionals and the public. The review identified a backlog of cases which were and continue to be addressed. 

In November, the Society convened a wearable blood pressure technology high level summit with more than 60 participants from Government, regulatory bodies, academia, NHS and industry. The meeting brought together relevant expertise to consider evaluation, data integration and research or pilot implementation. It established three workstreams and highlighted the need to match claims to evidence, consider equitable access and identify the policy conditions required for responsible adoption. 

The summit extended the Society’s convening role into an emerging area of blood pressure practice. It laid the foundations for subsequent programme development. Further work will be required to develop the evaluation approach, delivery arrangements and funding. 

## **Education Committee report** 

The Education Committee developed a coordinated programme for healthcare professionals and the public. New members joined in March, and working groups were established for specific projects. The Committee placed particular emphasis on translating knowledge into practice, supporting multidisciplinary learning and evaluating the usefulness of educational activity. A Society webinar on hypertension and atrial fibrillation was held with OMRON in March. The Society also contributed a well-attended session at the British Cardiovascular Society conference in June. The Committee reviewed the event and identified improvements for future meetings, including clearer audience-specific briefs, earlier coordination of communications and stronger links between sessions and exhibition activity. 

A bespoke six-session hypertension seminar programme was developed for One Wight Health. The session in May attracted 51 GPs and practice nurses and received positive feedback on its practical content and opportunities for discussion. The programme addressed diagnostic assessment, very high blood pressure, older adults and young people, with the concluding session scheduled for March 2026. Feedback and interest from neighbouring areas informed discussion of a more widely usable education model. 

The Emerging Hypertension Leaders Summer School took place in September in Cambridge, with strong demand for this pilot. The Committee’s approach included the positive evaluation of the programme and participant feedback to inform future delivery. 

With funding from Viatris, the Society developed an eight-module e-learning programme based on its guidelines and position papers. The Learning Rooms company was selected following a quotation process. Committee members contributed content and peer review, including material on young-onset hypertension, primary aldosteronism, resistant hypertension and hypertensive crisis. The programme remained in development during 2025, with completion and launch planned for 2026. 

The Committee agreed to explore a hypertension certificate or diploma, potentially at two levels to meet different professional learning needs and favoured a university partnership. Discussions also continued on specialist accreditation, training pathways and the relationship between assessed knowledge and specialist clinical competence. These were development projects rather than qualifications or accreditation schemes launched during the year. 

Not all planned activity proceeded. The joint Royal College of Physicians and Surgeons of Glasgow meeting was postponed, and the proposed CPPE pharmacy workshops did not progress to the full programme. Experience from these initiatives informed the planning and delivery of future external educational collaborations. 

**April 2009** 

**TAR** 

6 



## **Guideline Committee report** 

The Guideline Committee supported the Society’s role in reviewing evidence and translating it into practical recommendations for hypertension care. A major output was the July 2025 committee-approved version of the Call-to-Action position statement on blood pressure treatment thresholds and targets. 

The statement reviewed evidence from blood pressure lowering trials and called for a simpler approach to treatment initiation and control, with greater emphasis on timely treatment and avoiding therapeutic inertia. It also recognised the need to account for tolerance, frailty and individual circumstances. This represented BIHS’s position and call for changes to national guidance; it did not itself constitute a revision of NICE guidance. 

Guideline work was linked to the Education Committee’s e-learning development, including resources based on existing BIHS publications on young-onset and resistant hypertension, primary aldosteronism and hypertensive crisis. In July, the Education Committee proposed concise infographics to make key messages more accessible to clinicians. Improving dissemination and application of existing guidance was an important area for further work. The September draft protocol for the BHF and Joint British Societies guideline on prevention of atherosclerotic cardiovascular disease set out a further opportunity for hypertension expertise to inform wider prevention work. It proposed systematic evidence review, professional and livedexperience input, and a guideline capable of regular updating. BIHS’s specific representation and contributions should be confirmed before these are reported as Society deliverables. 

## **Research Committee report** 

The Research Committee worked with the British Heart Foundation Clinical Research Collaborative (BHF-CRC) on a national hypertension research priority-setting initiative. By the September 2025 draft report, the exercise had produced a ranked Top 10 intended to guide researchers and funders towards questions of greatest relevance to clinical care and people living with hypertension. 

The project used a modified Delphi approach informed by James Lind Alliance principles. A multidisciplinary steering group refined research questions drawn from guidelines and expert discussion. Successive surveys gathered professional and patient perspectives, followed by a facilitated consensus workshop. The September draft recorded 109 clinician responses and 36 patient responses to the second-stage surveys, with 24 participants in the final workshop. The priorities placed strong emphasis on whether cuffless devices perform well in clinical use, reducing inequalities in detection and treatment, and improving adherence to medicines. Other themes included dementia prevention, the effects of new obesity therapies, resistant hypertension, treatment in very old and frail adults, home versus clinic monitoring, and the thresholds and targets used to guide treatment. 

The exercise gave the Society a clearer basis for aligning scientific work with unmet needs in practice. Its emphasis on cuffless monitoring also provided a relevant foundation for the Society’s subsequent wearable technology programme. The intended next step was to translate the priorities into collaborative, fundable research and disseminate them to the wider cardiovascular community. 

Children and young people were included in the question-generation and survey stages, although no specific paediatric question reached the final Top 10. The draft acknowledged limitations in representation at the workshop and the need to maintain attention to paediatric questions and improve inclusion in future exercises. 

BHF-CRC also supported links between the Research Committee and the refreshed ECR special interest group, including access to collaboration opportunities, research development support and methodological expertise. Publication and further commentary arising from the prioritysetting work are addressed in the 2026 forward programme. 

## **Early Career Researchers (ECR) special interest group report** 

The ECR special interest group refreshed its membership and priorities during 2025. Recruitment brought new members from a wider range of disciplines and locations. At the October meeting, the group included expertise in clinical pharmacology, neuroscience, biomedical science and public health, strengthening its ability to represent different early career pathways. 

**April 2009** 

**TAR** 

7 



Section D                      Achievements and performance 

The group reviewed its purpose and planned updated Terms of Reference, with an emphasis on shared responsibility for collaborative outputs. BHF-CRC support offered access to research networks, seed-funding opportunities, document-sharing facilities and clinical trials methodology advice. 

October discussions identified priorities for publications, networking and the Annual Scientific Meeting. These included a comparative review of hypertension guidelines, a possible dedicated ECR event, and broader career-development content for non-clinical researchers and allied health professionals. Members also proposed clearer recognition of individual contributions within abstract submissions. These proposals established the agenda for 2026 rather than representing completed publications, events or changes to abstract policy in 2025. 

## **Clinical Practitioners special interest group report** 

The Clinical Practitioners special interest group strengthened its practitioner voice within the Society through refreshed membership, work on its Terms of Reference and closer links with the Education Committee through Sally Brett. The group represented the needs and expertise of nurses, pharmacists and other allied health professionals working across primary and secondary care. 

The September update reported publication of an article on hypertension and chronic kidney disease in Practice Nurse. An invitation to contribute a further article to RCNi on the AIM HYINFORM trial offered another opportunity to explain the relevance of research to frontline care. Exploratory discussions with the British Society for Heart Failure considered collaboration on multimorbidity. The group also explored practical education with Issues & Answers, including hypertension-focused Digital CRAFT Cards and a Virtual Clinics case involving hypertension and comorbidities. These resources were proposals or opportunities for involvement, with the cards dependent on funding, rather than completed BIHS products. 

Application terms prepared in November clarified the group’s remit, eligibility, expected contribution, meeting commitment and reporting relationship with the Education Committee. Future priorities included practical publications, education and case studies, further external collaboration and clinical input to the proposed 2026 awareness campaign, subject to funding. 

## **Section E                    Financial review** 

The Trustees aim has been to maintain reserves at four times the annual direct charitable **Brief statement** expenditure to guarantee sustainable charitable activities in the event of unfavourable **of the charity’s** financial circumstances and in particular loss of income from industrial partners.  As the **policy on** Society is in the process of changing its status to a CIO (with a trading subsidiary) and in **reserves** light of recent growth, the Trustees intend to revisit the policy to consider the impact of these changes with regards to the need for holding and spending reserves going forward. 

**Details of any funds materially in deficit** 


## **Further financial review details (Optional information)** 

**April 2009** 

**TAR** 

8 



You **may choose** to include additional information, where relevant about: 

- the charity’s principal sources of funds (including any fundraising); 

- how expenditure has supported the key objectives of the charity; 

- investment policy and objectives including any ethical investment policy adopted. 

The Society/s main income derives from membership, the Annual Scientific Meeting, Prevention Partners scheme, Industry support towards the Society’s programme of educational activities and investment income. In addition, restricted funds in the year were received from another charity primarily towards the Summer School initiative referred to above. The Society aims to only accept support from Industry partners on the condition that the activities undertaken and decisions made rest with the Society. Total Income for 2025 was £341k (2024: £232k). 

There was a deficit on unrestricted funds in 2025 of £139k (2024: deficit £24k) which was indicative of the investment in transitioning and modernising the Society (including one off costs e.g. strategic consultancy, legal fees, website development etc.) but also includes a devaluation in the year of £30k in the investment held noted below. 

The Society has had a long-term investment in an ethical investment fund with CCLA. The Trustees are conscious of the need to maximise returns whilst having regards to ethical considerations and intend to revisit the investment policy in the coming months and align it as needed with the reserves policy. 

## **Section F                     Other optional information** 

## **2026 Planned Activities, Delivery and Achievements** 

The 2026 programme builds on the organisational changes and scientific work undertaken in 2025. The activities below reflect the forward plans and achievements already realised. Delivery is subject to the relevant approvals, funding and capacity. 

- **Governance and operations -** Progress charitable incorporation and the constitution to be a Charitable Incorporated Organisation (CIO) with appropriate trustee arrangements and application.  This includes the setting up of a trading subsidiary with clear contracting and reporting arrangements. Also if deemed in the best interests of the Society, to look at opportunities to formalise close links with another charity with similar aims.  Consolidate financial oversight, records, operating procedures and the blood pressure device service. 

- **Scientific meetings and education -** The Annual Scientific Meeting in Liverpool in September 2026 was very well received. Other initiatives which have already taken place include a hypertension session at the BCS conference in Manchester. 

- **E-learning and public resources -** Complete and launch the Viatris-funded course comprising eight modules plus an introductory module, planned for free access through the BIHS website. Complete eight patient education animations with Blood Pressure UK, based on its existing approved patient information, with linked promotion through the two organisations. Coordinate communications so that the resources reach their intended audiences. 

- **Guideline dissemination -** Prioritise practical use of BIHS guidance in frontline services, particularly acute and emergency care, primary care and stroke medicine. Consider concise resources, webinars and cross-society partnerships, and agree a sustainable model for education requested by local systems. Confirm the Society’s role in the BHF and Joint British Societies prevention guideline programme. 

- **Research and Engagement plans -** Research priorities. Disseminate the national Top 10 and encourage collaborations and funding applications that address them. The 2026 materials include a British Journal of Cardiology commentary and editorial proof; their publication details need confirmation. Maintain attention to children and young people and to groups underrepresented in the priority-setting process. 

- **Wearable blood pressure programme -** Develop the evaluation, data integration, and research and implementation workstreams established after the November summit. Priorities include the multicentre platform study, protocol and supporting documents, steering arrangements, site and manufacturer engagement, and funding. Develop implementation relationships with the Health Innovation Network and research partners. 

**April 2009** 

**TAR** 

9 



- **ECR development -** Progress the comparative hypertension guidelines manuscript (including the Liverpool ASM 2026 session on career journeys) and research opportunities across clinical and nonclinical pathways. Explore a mentoring scheme linked to placements, a dedicated ECR day and opportunities for journal contributions and peer review. Funding continues to be sought to support activities. 

- **Clinical practitioner activity** - Continue practical publications and develop the proposed Issues & Answers resources if funding and arrangements are agreed. Build collaboration on multimorbidity, strengthen links between practice and research, and contribute practitioner expertise to educational events and the proposed awareness campaign. 

- **Policy and awareness** - Strengthen the Society’s contribution to national hypertension and cardiovascular prevention policy. A New Statesman supplement and Westminster reception around World Hypertension Day took place in May 2026. In addition, planned activity included public awareness and member communications. Develop the policy and positioning materials needed for sustained engagement with decision makers. 

- **Membership and partnerships -** Improve recruitment, retention and engagement through the new membership platform. Expand Prevention Partners and develop funded webinars, supplements, campaigns and events, with clear oversight and scientific independence. 

## **Section G                    Declaration** 

**The trustees declare that they have approved the trustees’ report above.** 

**Signed on behalf of the charity’s trustees** 

**Signature(s) Full name(s) Phil Chowienczyk Position (e.g. Sec, Chair, etc.) President** 

**Date** 26/10/2026 

**April 2009** 

**TAR** 

10 



BRITISH AND IRISH HYPERTENSION SOCIETY
(Charity Rogistration Number 287635 (England and Wales)
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

BRITISH AND IRISH HYPERTENSION SOCIETY
CONTENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
*OT.tents
LEGAL AND ADMINISTRA TIVE INFORMATION..........-.........-.......................ERRORI BOOXMARK NOT DEFI,IJED.
,'NDF-.PENDENI" F.XAMINER'.S REPORT...................-............................................................................................,
STA TEMENT OF FINANCIAL ACTIVITIES...........-..-.....-...--.........-.......-..........................................................
SALANCE SHEET
NOTES TO THE FINANCIAL STATEMENTS .............................................-..........................................................

BRITISH AND IRISH HYPERTENSION SOCIETY
LEGAL AND ADMINISTRATIVE INFORMATION
Tru.stees
Professor Phil Chowienczyk
Professor I Imlkinson (Resigned 16 September 2026)
Dr Luca Faconti
Professor Dame Anna Dominiczak (Appointed 16 September 20261
Dr Philip Lewis (Appointed 16 September 20261
Dr James Sheppard IRe5igned 16 September 20261
Dr C.orislopher Clark (Appointed 16 September 20261
Mr Sam Olden (Resigned 16 September 2028}
Dr Tahreem Butt (Appointed 16 September 20261
Dr P Gupta (Resigned 15 November 20251
Dr Ryan McNalty
Dr Helen Watren
Dr Manish Saxena
Charity number {England and Wales)
287635
Princlpal Address
Clo The Wolfson Institute
Chartethouse Square
Lolldon
EC1M 6BQ
Independent Examiner
HJS (Reading) Limited
3 Richfield Place
Richfield Avenue
Reading
Berkshire
RG1 8EQ

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
BRITISH AND IRISH HYPERTENSION SOCIETY
I rgport lo the trLtslees on my examination of the financial statements of the British & Irish Hypertension
Society Itne Charity) for the year ended 31 De￿mber 2025.
Rpspon$lblllties And basls of report
t the trustees of the Charity you are responsible forthe prepara￿n of the financial stalemonts in accorrJari"e
wi:J) the requirements of the Charities Act 2011.
I report in respect of my examination of the Charity's fina￿la1 stslemenls carried out under Section 145 of the
Charities Act 2011. In carry7ng out my examination I have followed the Directions given by the Charity
Commission under section 14515)Ibl of the Charibes Act 2011.
Indèpendent examlner's statemènt
Your attention is drawn to the fact that Ihe charity has prepared the financial statements in accordance with
the. relevant version of the State￿￿nI of Recommended Practice applicable lo charit*s preparing their
financial statements in accordance wth the Financial Reporting Standard applicable in the UK and Republ￿ cf
Ireland IFRS 1021 in preference lo the AlzotsnlK￿ and Reporting by Charib'es.. Slalernent ol Recommended
Piactice issued on 1 April 2025 which is referred lo in the extant regulations bul has now been withdrawn. I
understand that this has been done in order for the financial statements to prwde a true and fair view in
accofdanre with UK Gerterally Accepted Accounts"ng Practs"￿.
l tr.ave completed my examinab'on. I confimi Ihal no mallers have come lo my attention in connection with the
examination giving me cause ¢0 believe that in any malerial resi*d=
accounting records were not kept in respect of Ihe Chanty as required by Section 130 of the Charities
Act2011.
2. the fir,ancial slalements do not accord with tho$8 records." or
3. Ilie financial stat8ments do not compFy wth the applicabla requirements concerning the form and
conleilt ol the iinancial slalements sel in the Charities (Accryjnts and Reports) Regulations 2008
other than any requirement that the financial ststements give a true and fair view. whid) is not a matleT
considereLI as part of Ihg ind8pgndenl examination.
I have no concerns and have come across no other matters in conn8Ction wrth the examrnation lo which attention
should be drawn in this report in ord8r to enable a proper understanding of the financial sl8lements lo be
reached.
Mark Rogers
CCA
14JS IRe.adingl Limiled
3 Richfield Place
hiield Avenue
Rpading
Bèrkshire
RG1 8EQ
2e Octobar 2026

BRITISH AND IRISH HYPERTENSION SOCIETY
STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE
ACCOUNT
FOR THE YEAR ENDING 31 DECEMBER 2025
Unrestiictsd Restiictè
Funds
Funds
Totl Unth1d￿ Restrictwj
Funds
Funds
Funds
J24
FJiids
Mots
lTrconefrom',
,' ￿ an¢ ￿a¢1P.5
21525
J6.￿ 1￿,458
18297
17,610
0,728
1ll078
214,168
11297
295,728
rotl',ncome
,OW 2J2,Oie
Eyr:ditureor.,'.
Ckn13bleAcbwhes
Totsl aJpend'.Iiire
404,811
Wll
57 495,W 211,7
93,657 491
211,730
12,4
Nelll(s5Vgarts on ir￿￿51n11[s
10
111,155
,1&5
15,744
Net lexF¢ndilu?Ifincuneand
niGveTr,entin fvnds
1139,2381 114,6511 1181,891 (￿,￿)
47,
RKoryciliation offur,,ds.'
Fundr brough￿ lorwate *,1 Janu2rv?Q25
F￿nd.* caffied forward a131 Decemkr20
5154 749210 D).5
5e4,315
6%,646
51561
749,210
'rhe statement of financial activities includes oains and bsses recognised in the year. All income and
expenditure derive rrom continuing activrties.

BRITISH AND IRISH HYPERTENSION SOCIETY
BALANCE SHEET
AS AT 31 DECEMBER 2025
2025
2024
Notes
Fi.xed assels
Tanqible a¢sets
CLirent assets
Deb:,ors
Inveitmenl,.
C4SiI at bank and in hand
12
13
127,915
570,273
25,124
723,312
130,3?7
Crphlitors: amounts falling due within one y&r
14
(158,9971
153.721.:
Net current assets and net asspts
564,315
749,2111
Representpd by..
Res.ricted fund.8
UDrpslfiCted funds
16
6,907
S57,408
696.616
749,21G
The financial stalewenls were appfoved by the Trnstees on Monday 26 October 2026 and signed on ils Doha.'I
jy
)r Luca Faconti
Tru¢lep.

BRITISH AND IRISH HYPERTENSION SOCIETY
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
1. ACCOUNTING POLICIES
Charrty Information
British and Iiish Hypertenston Sooety is a registered chanty. Further details be found * ￿Y.b1hs.0r9.Vk.
Accounting Convention
The fina?cial statements have been prepared in ￿arCe v*th the Charity's goveming document, the Char4ties
Act 2011, FRS102'The Financial Reporbng Standard applicable in the UK and Republ&c of Ireland. and thL
Charities SGRP- Accwnting and Repw)rting by Charities". Statement of Reo)mmende¢Y Practicè applrable to
charrties preoaring thèir accoL'nts in accordance with the Finanaal Reporting Stsndard applicable in the UK f24lQ
Republic o! Ireland IFRS 1021. The chap.ty is a Public 8enefft Enlty as dèfined by FRS 102.
The tha..ty has taken advantage of Ihe provisk)n5 in the SORP for charities not to prepare a statement of cash
flow's. The fiilano81 st*ements are tyepared in sterting which is the functional currency of the charity. Monetar/
amounts in these financial statements are rounded to Ihe nearest £.
Tb.e finaiual statements have been prepared under the histuical cost ¢onventi¢)n. The priwpal accounting
policies are set out bdow.
Golng Concem
At the time of approving finanoal statements, the Trustees have a reasonable expectation that the Charity
h2s adequate resources to conts.nue in operat¥Jnal existence foi the foreseeable fU￿re. Thus the Trustees
conty'nue to adopi the gowjg Cer￿ern basis of accounb.ng in preparing the financial statements.
Charitable Funds
Unrestrictecs funds are available for use at the discretK)n of the Trustees in fijrtherance of their chalitable
objectives. P.e5tricted funds are subject to ¥rfiSc conilitrons by donors or grantors as to they rnay be used.
The purposes and uses of the ￿$tr￿ted fuThJ$ are ￿t out in the notes to the ffiancial siatem&nts.
Income
Income is re
gnised whert thA Chaty is ￿allY errtilled to rt after arty performance condib.ons havg me:,
the 3mo'.Jnts ¢an be measured reliabty and it is probable that in￿rne wll be r￿1ved.
C8sh donations arè recijgnised on receipt. Other dcwjations are recognised On￿ the Charity has been notified of
the donation, unless performa4ce conditions requi￿ deferral of the amount. Income tax recoverable in relalirjll lo
donaboDS received under Grft Aid or Deeds of Covenant Is reGognised at the ts.rne of the donation.
Legaaes are rewrrised on receipt w otherw*ise Chaiity has been nob.fied of an impending distribution, the
amount is known an¢J re￿Ipt 1> expected. If the arTtount ts not known. the legacy is treated as a contingent aisei.
Turnover is measured at the fair value ofthe (aMsideratson or rece￿a￿ and ￿preseTrts amounts
receivable for goods and serytss provided in the norn￿1 ￿r$e of business. net of dis￿Unts and VAT.
Ex￿ndItUre
Expenditure is recognisèd once there is a ￿al or construciNe obligation to transfer ecnnomic benefit to a third
party, it is probable that a transfer of eo>nomic beneffts will be required in settlement, and the amount of the
obligation ran be measured ￿lIablY. Expenditure is accoLTnted for on the a(truals basis.
ExpenditUTe is dassffied by activity. The costs of each activity are made up of the total of direct costs and =hqre
cos".s, inJL.d4ng support costs invofved in iJndertaking each activity. Direct cosls attributable lo a single actioi-.>'
are allocatets dI￿dY to thai adivty. Shared costs whrth contribute to more than one a(*vity and support C￿t>
wtjich ar8 not attributable to a single activity are apportioned between those a￿iv￿leS on a basis cons15tent ¥￿ILl
the use of resources. The Charity ¢*)es not presenuy have any stsff.

BRITISH AND IRISH HYPERTENSION SOCIETY
NOTES TO THE FINANCIAL STATEMENTS (Continued)
FOR THE YEAR ENDED 31 DECEMBER 2025
Cash and cash equivalents
Ca¢h and ￿$h eq4Jivalents i￿JUde cash hand, deposrts W at OHII with banks. other short-lemi liquid
investmanls with onginal n7atuvrties of Ihiee months or less.
Financi<il Instruments
Tbe Charitv has elected to ap￿Y the provisions of Sedion 11 'Basic Finan0￿ Instruments" and Sectson 12 "Other
Financial Instrurnents IssLtes' of FRS 102 10 all of tts finanoal instruments.
Finanoal Instruments are reccgnised in the Chanty's balance sheet when the Chaiity becomes paty to the
contractual provisions of the irtstrument.
Financial assets and liabilities are offset. with the nèt amounts preserrted in the financial slalements. wjien thpre
is a legally enforcEable nght to sel off the recognised amounts and the￿ is an rntention tts settle on a net basis or
to realise the asset and settle the Irabdty simuttaneousty.
Basic financial assets. which include deblors and cash and bank baLl￿s, are initi.ally measured at tr8nsedon
pnce including transaction costs and are subsequentty carried at amoib.sed cost using the effective interest
method unless the afTangemeot constiiutes a finanong transaCi￿n, where the transacbon 15 measured at tie.
pre•￿ent valuè of the future ieceipls discounted at a mathet rate of interèst. Finanoal assets dassiled as
fee*iv3ble within one year a￿ not amoth"sed.
Basis finanaal Irdbilrtses, induding ¢xditors and bank loans are initially recogni5ed al transaction price unless the
arr¢ngemeni ccinslilutes a fin2nang transactton. where Ihe debt instrument is measured at the present value of
the future payments disCO￿ted èi a mathet rate of interest. Financ4al liabJ"lities dassified as payable within one
year are not amOr￿sed.
Debt instrJJments are Subsequent￿ carried at amorbsed ￿$1. using the effective inierest rate method.
Trade creditors are obligations to pay for goods or services thai have been acquirèd in thè ordinary course of
operab.ons from suppliers. Amounts payable are da5Stfied as curyent liabilities rf payment is due within one yeer
or less. If not, they a￿ presented as non-current liabiliiies. Tra¢Je creditors are recognised initially at transactlDn
price and suosequentty measured at amortised cost using thè efl8kn irtter￿t method.
Financial liabilitt'e$ are d&recc¥nised when Ihè Chariws contractual Oblig8t￿nS ex￿"re or arè discharged or
Can￿lled.
Critical aceounting estimates and judgements
In the application of the Charity's a￿UntIng Wicies. the Twstees a￿ required to make judgements, estimatB$
arid 8ssump:ions about the carrying amount of assets and liabiltti.es that are not readily apparent from other
sources. The estimates and assooated assumpb"IH)s are based on historical experrence arKI other factorB Ih£t ère
considered to be relevant. Actual resurts may differ from estimètes.
The estiniatpx and underfytng assumpb.ons a￿ revie￿￿ on an ongoirg basis. Revisions to ac£ounting estirn.ates
are recognis_* in the penod ip. which the ests.mate is revised where the ￿VtS10n affects only that period. or 4n tnp
period o* the revision and future periods where the revision affects both (￿rrent and fulu¥e penods.

BRITISH AND IRISH HYPERTENSION SOCIETY
NOTES TO THE FINANCIAL STATEMENTS (Continued)
FOR THE YEAR ENDED 31 DECEMBER 2025
DONATIONS
Total
2025
Total
2024
Donation- Awlar￿d
Gfft. in Kind
Other donations
15.000
10,500
25
25.526
The Gift in Kind above relates to the markel value of faalitatillg the British and Irish Hypertension's hioh level
Summit Imeeting o? 20 Novembei 2025 as provided by IQVIA at no t￿$t lo the Charity. The grft covered tha cost¢
of IQVIA management time. the venue, equipment use, catering and wrtbng se￿￿eS and design for the ever.l.
CHARITABLE ACTMTIES INCOME
Tol&l
2025
2024
2024
17,362
SuÉrthficlAeebrg
17a62
16.rn
114.445
HYk*rterS￿n'PwrthnPatr￿,
hypè1*￿0ne￿￿w
(knrookerwniaye
TrdrrJryJ semn
Oeni¥bbp aFf*>t*)r4
T(01
35,9
17.1
251,906
154.468
60.co)
214,468
Ch2ritablè incorne disdosures have been expanded (l￿￿dI￿3 red8SStfying the pr*)r year comparatNes as shown
above to give greater understsndtng of the actwilres that the Charity is undertakir¥Jl. in particular in light of recent
expansion and diversification of activities.
4. INVtSTMENrs
Total
2025
T(>lal
2024
Dividends and interest ￿ceIvable
18,297
18,297
17,610
17.610

BRITISH AND IRISH HYPERTENSION SOCIETY
NOTES TO THE FINANCIAL STATEMENTS {Continuad}
FOR THE YEAR ENDED 31 DECEMBER 2025
S. EXPENDITURE ON CHARITABLE ACTivrriES
Svpport
costs
2024
Totsl
Costs
2024
202S
2025
1024
.mbership
Annijal
EducathX21 lun¢led prcgramn
HypertenSh￿'pre￿nttt￿ Part￿,
perteTrS￿ Ctyls
F*Ity￿hIp costs
TTriTriig sÈrnin*5
BIH.$ Summrf."
str¥.egrlfj￿ra,.￿nal de￿{(￿￿1
Tots.l ¢haritsbl8ewndityro
447
17,632
19.910
1,737
1714
p4
95,711
101393
11&621
10.086
4f1
976
128,￿8
18.49
4.165
85.049
12.4
41.459
44697
1.365
14.149
14.149
14.832
157,020
410.147
17,917
189.665
31665
04321
19.620
155.340
59.870
224.165
Ch2ritable expenditure disclosures have been expanded {iThJuding r*Jassrfying the pn.or year comparatlVEsI a:
shown above to gwè greater understsnding of the ￿1vit1"eS that the Charity is undertakn"ng, in particular in 11ghi of
ffw￿nt expansion and divetsifi&ion ol activtties.
BIHS Sumrnit o)sts indude £10.XKJ Gfft in Kind costs as explained in Note 2.
Supptsrt ￿St5 allocated to &#ivrtEs a￿ as fd10￿..
Gen&ra Seuetaii8t
cornsujtar￿y-da￿Insl￿￿ft
Fi￿r¢• s￿9￿0p.
cubve 2ne CthTmllee meeb.ry
E*er,ial chariry
Subscrptsns
Conwter3nd Eofr*are costs
Tar￿£
Leg81 ree5
88nk revaluaiois
enerthil knx¥rine¢5 0)sts
0￿re0St$
Totrdl stspport costs
17.767
30,15¢
17,284
3.216
2,707
4.183
1,033
85.321
3.￿1
Analysed bèty¥een'.
charitab￿ A¢tw￿e5
Support costs above indude g0Veman￿ cO￿S of £7.9)312024." £4,463) in respect of ExeoJtivÈ and Commillee
Mee)'ngs and Independent E¥aminerfs ￿$ts.

BRITISH AND IRISH HYPERTENSION SOCIETY
NOTES TO THE FINANCIAL STATEMENTS (Continued)
FOR THE YEAR ENDED 31 DECEMBER 2025
6. CHARITABLE EXPENDITURE BY FUNDS
Funds
Funds
207S
Funds
a)¥
Tolal
Fund$
2024
Funds
YJ24
Funds
2024
rknw5hw)
nijal ScI￿1rtic l*eb'ng
EeurAK)Tr￿ fund8d prcgww.&5
typertenslon.Prwbt￿ Parthws,
Hypertension e-prq&t Costs
Fellv*shw 05
TraFnng ￿1￿￿5
81HS Surrmit
Sti?£g￿(￿)er¢¢i0nol
Totsl chaii tsble •xpendith
159$
101393
1fS.621
10.016
10139J
976
975
126,aO
18,496
4.165
126,
10,086
12,435
4.165
74.149
14.149
17,917
188.fj85
8f1
17.9f7
189,685
495.4&8
211,7X)
12,4
7. NET MOVEMENT IN FUNDS
Net. rrK)venp.nt in funds is stated after charging."
Total
2025
Total
2024
Fees pay8bie to the Chartys independent ey2rr¥ner
independent ey2nin&"on- Charitys financial stalerrents
other a£suran¢e services
1.835
1.570
160
8. TRUSTEES REMUNERA TION AND EXPENSES
NoTr.e of the Trustees or crynrrrittee membern lor pe￿￿5 fA)nnected with thgm) received any remuneratson during
the year.
During the ye2r the Charity rermbursed travel expenses amounts to £78312024.. £607). The number of Trust
members reimbursed was 712024.. 6)
EMPLOYEES
The Charity no employees during the year12024". Nil) and the{efo￿ no salaiies g￿ater than £80,000.
10. NET ILOSSESIIGAINS ON INVESTMENTS
Total
2025
Totsl
2024
Unrealise(I Ilossllgain on COIF account
30,15S
75.744

BRITISH AND IRISH HYPERTENSION SOCIETY
NOTES TO THE FINANCIAL STATEMENTS (Continued)
FOR THE YEAR ENDED 31 DECEMBER 2025
11. TAAATION
The Charitv is exempt fro.m taxation on its actiwtres as al of rts income 15 applied for charitsble purposes.
12. DEBTORS
Total
2025
Total
2024
Trade debtcrs
Otrier debtors
Prepayments and accrued incowe
67,600
30,2Q3
30,112
127,915
600
16,848
3.672
21.120
13. CURRENT ASSET INVESTMENTS
Total
2025
Total
2024
Uilisled inveslnEnts
570,273
651,444
14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
Total
2025
Total
2024
Trède creditors
AccruaL8
De.'erred Inc
0ib.er credrtors
42,109
22,518
93,970
9,918
18,803
25,000
158.997
53,721
15. DEFERRED INCOME
Total
2025
Totsl
2024
Deferred in¢on* at 1 JaD.uary 2025
Released in the year
Rasource¢ Ileferred in the year
Deferred incon* al 31 OeceTrkner 2025
25.000
12S.000)
93,970
25,000
93.970
25,000
Deferred income relates to £53.135 for Hypertension e-proiects12024-. £N￿l, membership £2.800 (2024.. £Nil) a,Id
Hypertension P￿ventIon Partners £38.03512024". £25,c￿l.
10

BRITISH AND IRISH HYPERTENSION SOCIETY
NOTES TO THE FINANCIAL STA TEMENTS (Continued)
FOR THE YEAR ENDED 31 DECEMBER 2025
16. TOTAL FUNDS
Ftsr
Fw
1kn20
JI Q•c2Q25
{4011111
R4*trkt4d Fufx¥
130.IS6J
$57,4QJ
£5￿Y FL
1.7$5
1,862
6.248
6,9Ql
Tgtal Fur
749J•O
30.1JS
564,315
un￿&tr*I•d FL"
G¢r%r*
31 0•¢2Q24
720.551
172.0
1211.730)
15.744
R4Jtrkt*d Fu
S*.643
F$AJy Flf
45.564
7.00)
S2.564
112.4JS1
Totsl Fynd*
ns.$
1224.1f
15.744
749.210
The unresiri￿ed Fund¢ of the Charity o)mprise Ihe unexpended balarw of donations, grants and other incum&.
generaled wiiej) is not subje¢t to speafic condrtions by those conthbuting as lo how they rnay be used. These
ipclude designated funds which have been set asidè out of unresthctÈd ftrnd by the Twstees for specsfic
purposes.
T￿,e Summw School Restricted Funds arise from amounts granted by the Foundatton for Circulatory Heatth
IFFnHI towards fvnding ofthe Sooety'5 Emerging Hypertension Leaders Summer &hool whith took place. in
2025. As Ihe costs of the Sumrnei School were less than anticipated. FFCH agreed the ex￿$$ funds coulcl be
utili.-AJ for ¥oertain other educatr.onal actNi:ies undertaken by the Charity. The Essay Resln£#ed Fund derives fron
contributions received to suppJrt the Stanley Peart Prize to individuals lor their I￿￿k.
17. ANALYSIS OF NET ASSETS BETWEEN FUNDS
UrffPStiict•d
Funds
Restrthd
Totsl
25
2J2?
As al 31 D9cemter&
Cunbrrtass8￿1ydbth$}
561,315
Furtts
FL¥
P68131 kn2024
Cun&r,13S58NIth,1tss1
749.210

BRITISH AND IRISH HYPERTENSION SOCIETY
NOTES TO THE FINANCIAL STATEMENTS {Continued)
FOR THE YEAR ENDED 31 DECEMBER 2025
18. REiATED PARTY TRANSACTIONS
Othar than expenses re1m￿r5ed to Trustees as disdosed in Note 8, Ihere no olher related paty
Iransaclitsns.
12

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
BRITISH AND IRISH HYPERTENSION SOCIETY
I report to the trustees on my examination of the financial statements of the British & Irish Hypertension
Society (the Charity) for the year ended 31 December 2025.
Responslbllltles and basls of report
As the trustees of the Charity you are responsible for the preparation of the financial statement5 in accordance
with the requirements of the Charities Act 2011.
I report in respect of my examination of the Charity's financial statements carried out under section 145 of the
Charities Act 2011. In carrying out my examination I have followed the Directions given by the Charity
Commission under section 14515llb) of the Charities Act 2011.
Independent examlner's statement
Your attention is drawn lo the fact that the charity has prepared the financial statements in accordance with
the relevant version of the Statement of Recommended Practice applicable to charities preparing their
financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of
Ireland IFRS 1021 in preference lo the Accounting and Reporting by Charities.. Statement of Recommended
Practice issued on 1 April 2025 which is referred lo in the extant regulations bul has now been withdrawn. I
understand that this has been done in order for the financial statements lo provide a true and fair view in
accordance with UK Generally Accepted Accounting Practice.
I have completed my examination. I confirm that no matters have come to my attention in connection with the
examination giving me cause to believe thal in any material respect..
accounting records were not kept in respect of the Chaiity as required by Section 130 of the Charities
Ac12011.
2. the financial statements do not accord with those records., or
3. the financial slalements do not comply with the applicable requirements conceming the form and
content of the financial statements sel out in the Charities {Ac¢ounts and Reports) Regulations 2008
other than any requirement that the financial slalemgnls give a true and fair view. which is not a matter
considered as part of the independent examination.
I have no concerns and have come across no other matters in connection with the examination to which attention
should be drawn in this report in order to enable a proper understanding of the financial statements to be
reached.
Mark Rogers
CCA
HJS (Reading) Limrted
3 Richfield Place
Richfield Avenue
Reading
Berkshire
RG18EQ
28 October 2026